CRISPR-Cas9 System In Vivo Delivery to Combat HBV
Article Sidebar
-
hepatitis B virus, CRISPR/Cas9 delivery, AAV vectors, in vovo gene editing Virus hepatitis B, CRISPR/Cas9, In Vivo, Vektor AAV
Abstract
Background: Hepatitis B Virus (HBV) infection remains a major global health issue despite the availability of HBV vaccine. The novel CRISPR-Cas9 gene editing technology efficiently helps to cure HBV by disruption or cleavage of HBV DNA. Aims: Several in vitro and in vivo studies have demonstrated the effectiveness of HBV-specific clustered regularly interspaced short palindromic repeat (CRISPR)/associated protein 9 (CRISPR/Cas9) systems in cleaving HBV DNA. Methods: In vivo, delivery of the CRISPR/Cas9 system at target sites remains a major challenge that needs to be resolved before its clinical application in gene therapy for HBV. Results: In this review article, we comprehensively evaluate the progress, challenges, and therapeutic potential of CRISPR-Cas9 gene therapy for HBV using adeno-associated virus (AAV) vectors as delivery vehicles. Conclusion: The CRISPR-CAS9, HBV, AAV, delivery methods of CRISPR-CAS9 component in vivo, challenges, and future perspectives in harnessing this innovative technology to combat HBV infection.
Full text article
References
Boni, C., et al. (2007). "Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection." Journal of virology 81(8): 4215-4225. https://doi.org/10.1128/jvi.02844-06
Kayesh, Mohammad Enamul Hoque & Amako, Yutaka & Hashem, Md Abul & Murakami, Shuko & Ogawa, Shintaro & Yamamoto, Naoki & Hifumi, Tatsuro & Miyoshi, Noriaki & Sugiyama, Masaya & Tanaka, Yasahito & Mizokami, Masashi & Kohara, Michinori & Tsukiyama-Kohara, Kyoko. (2020). Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNA. Virus Research. https://doi.org/10.1016/j.virusres.2020.198191.
Kennedy, E. M., et al. (2015). "Targeting hepatitis B virus cccDNA using CRISPR/Cas9." Antiviral research 123: 188-192. https://doi.org/10.1016/j.antiviral.2015.10.004
Kostyushev, D., et al. (2023). "Depleting hepatitis B virus relaxed circular DNA is necessary for resolution of infection by CRISPR-Cas9." Molecular Therapy-Nucleic Acids 31: 482-493. https://doi.org/10.1016/j.omtn.2023.02.001
Lin, G., et al. (2015). "Application of CRISPR/Cas9 technology to HBV." International journal of molecular sciences 16(11): 26077-26086. https://doi.org/10.3390%2Fijms161125950
Lin, S.-R., et al. (2014). "The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo." Molecular Therapy-Nucleic Acids, 3. https://doi.org/10.1038/mtna.2014.38
Liu, Y., et al. (2018). "Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus." Antiviral research 152: 58-67. https://doi.org/10.1016/j.antiviral.2018.02.011
Lv, W., et al. (2021). "The Application of the CRISPR/Cas9 System in the Treatment of Hepatitis B Liver Cancer." Technology in Cancer Research & Treatment, 20. https://doi.org/10.1177%2F15330338211045206
Ramanan, V., et al. (2015). "CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus." Scientific reports 5(1): 10833. https://doi.org/10.1038/srep10833
Redman M, King A, Watson C, King D. What is CRISPR/Cas9?. (2016). Archives of Disease in Childhood-Education and Practice, 101(4), 213-215. https://doi.org/10.1136/archdischild-2016-310459.
Schiwon, M., et al. (2018). "One-vector system for multiplexed CRISPR/Cas9 against hepatitis B virus cccDNA utilizing high-capacity adenoviral vectors." Molecular Therapy-Nucleic Acids 12: 242-253. https://doi.org/10.1016%2Fj.omtn.2018.05.006
Zhu, W., et al. (2016). "CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse." Virus Research 217: 125-132. https://doi.org/10.1016/j.virusres.2016.04.003
Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.